Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Haolin Ni who wrote (632)	5/5/1998 12:18:00 PM
From: StockDoc	Respond to of 2135

HN, I'm totally cool, need no more calm down. StockDoc To your notes: I'm not sure you understand the word, "fact". What you present as facts are interpretations of anecdotal information. As a clinician and experimental scientist, I usually know what experimental tumor treatment data I trust and which are B.S. Folkman's models are pretty good as they are. They target well established metastasizing tumors that would ultimately lead to death and are not treatable with standard chemotherapeutic modalities in these animals. Data I saw reported by others, with other drugs, in other mouse models, were never as good as these. Many cancer drugs can cure mice with early cancer, in fact, many cancer drugs were developed using such models. Some even work in certain types of tumors (see good results in childhood leukemia). But no drug can cure animals (or people, for that matter) with advanced, metastasizing lung cancer. Many patients get to the doctor with late (i.e., advanced) stage cancer which cannot be cured. Accordingly, cancer mortality approaches 500,000 people per year (in the U.S.). This incurable patient population is ENMD's target, and the animal models have to be predictive: incurable with other drugs, marketed or under development. The Harvard lab did the basic experiments. I'm sure that the university works on further refinements, such as trying to cure advanced (!) spontaneous breast cancer in mice, or carcinogen-induced and other tumors other animals. Those would be pretty good confirmatory data to all the above. As far as I can recall, ENMD is not giving out many press releases, keeping the numbers at the bare minimum. Stockholders want press releases though, so they probably put out a few. What specific releases do you refer to. ENMD seems to delegate information marketing to Dr. Folkman and professional networks (Harvard, NCI, NYT, CNN, etc.). See the results yesterday. As of your advice of "out this", that sounds simplistic for my taste. By the time you were awake yesterday, I made my financial goal for the year and still have the same stake in ENMD. I'm watching the exciting show now. I may buy more in the teens, unless something better comes along. I do not advise anyone to buy anything with the exception of a single private message that I posted on this thread - I recommended the fellow to buy ENMD in the 11 to 17 range (buddy, you can confirm).